The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …

New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

Is anyone with intermediate-risk prostate cancer a “good” candidate for AS?

There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …

Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Three-year biochemical recurrence after Retzius-sparing RALP

Back in January this year we commented on a technique known as Retzius-sparing radical prostatectomy, which — according to its advocates — is said to facilitate recovery of erectile function post-surgery. … READ MORE …

Low-dose-rate brachytherapy monotherapy at the Mayo Clinic

A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …

Prediction of risk for aggressive prostate cancer among Black males

A newly published paper has now suggested that data from a single PSA test carried out when the men are between 40 and 64 years of age can be used to project risk for aggressive prostate cancer among African-American men. … READ MORE …